Trexquant Investment LP Sells 715,377 Shares of Amicus Therapeutics, Inc. $FOLD

Key Points

• Trexquant Investment LP significantly reduced its stake in Amicus Therapeutics by 74.1%, ending the first quarter with 250,672 shares valued at approximately $2 million.
• Wellington Management Group LLP and Nuveen Asset Management LLC increased their holdings in Amicus Therapeutics, with Wellington owning over 29 million shares after a 2.6% increase.
• Analyst sentiment is mixed, with Morgan Stanley upgrading the stock from "equal weight" to "overweight", while Wall Street Zen downgraded it from "buy" to "hold," resulting in a consensus rating of "Moderate Buy" with a target price of $16.22.

Trexquant Investment LP lessened its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 74.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 250,672 shares of the biopharmaceutical company's stock after selling 715,377 shares during the period. Trexquant Investment LP owned approximately 0.08% of Amicus Therapeutics worth $2,045,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in FOLD. Raymond James Financial Inc. bought a new stake in shares of Amicus Therapeutics during the fourth quarter worth approximately $132,000. Hsbc Holdings PLC boosted its holdings in shares of Amicus Therapeutics by 82.6% during the fourth quarter. Hsbc Holdings PLC now owns 41,920 shares of the biopharmaceutical company's stock worth $395,000 after acquiring an additional 18,964 shares during the period. Northern Trust Corp boosted its holdings in shares of Amicus Therapeutics by 5.9% during the fourth quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company's stock worth $31,761,000 after acquiring an additional 187,652 shares during the period. Jane Street Group LLC boosted its holdings in shares of Amicus Therapeutics by 7.8% during the fourth quarter. Jane Street Group LLC now owns 324,270 shares of the biopharmaceutical company's stock worth $3,055,000 after acquiring an additional 23,524 shares during the period. Finally, Ameriprise Financial Inc. boosted its holdings in shares of Amicus Therapeutics by 4.2% during the fourth quarter. Ameriprise Financial Inc. now owns 403,127 shares of the biopharmaceutical company's stock worth $3,797,000 after acquiring an additional 16,179 shares during the period.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on FOLD. Wall Street Zen downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, August 30th. Morgan Stanley upgraded shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research report on Thursday, July 17th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Amicus Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.00.

Amicus Therapeutics Price Performance

FOLD traded up $0.05 during trading on Wednesday, hitting $7.94. 3,540,957 shares of the stock traded hands, compared to its average volume of 3,787,990. Amicus Therapeutics, Inc. has a twelve month low of $5.51 and a twelve month high of $12.65. The company has a market cap of $2.45 billion, a price-to-earnings ratio of -66.16 and a beta of 0.55. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29. The business has a 50 day moving average price of $6.87 and a 200 day moving average price of $7.03.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.